Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma

被引：0
作者：
Thomas Powles
Robert J. Motzer
Bernard Escudier
Sumanta Pal
Christian Kollmannsberger
Joanna Pikiel
Howard Gurney
Sun Young Rha
Se Hoon Park
Poul F. Geertsen
Marine Gross-Goupil
Enrique Grande
Cristina Suarez
David W. Markby
Alan Arroyo
Mark Dean
Toni K. Choueiri
Daniel George
机构：
[1] University of London,Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary
[2] Memorial Sloan Kettering Cancer Center,British Columbia Cancer Agency
[3] Gustave Roussy,Macquarie University and Westmead Hospital
[4] City of Hope National Medical Center,Severance Hospital
[5] BCCA Vancouver Cancer Centre,Herlev and Gentofte Hospital, Herlev Hospital
[6] Wojewodzkie Centrum Onkologii,Vall d’Hebron University Hospital and Institute of Oncology
[7] Macquarie University,undefined
[8] Yonsei Cancer Center,undefined
[9] Samsung Medical Center,undefined
[10] Copenhagen University,undefined
[11] Groupe Hospitalier Saint André,undefined
[12] Hospital Universitario Ramón y Cajal,undefined
[13] Universitat Autònoma de Barcelona,undefined
[14] Exelixis,undefined
[15] Inc,undefined
[16] Dana-Farber Cancer Institute,undefined
[17] Duke University Medical Center,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：663 / 669
页数：6
相关论文
共 81 条
[21]  
Hammers Hans J(2013)Pazopanib versus sunitinib in metastatic renal-cell carcinoma N. Engl. J. Med. 369 917-927
[22]  
Donskov Frede(2015)Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients Eur. J. Cancer 51 591-597
[23]  
Roth Bruce J(2016)Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Lancet Oncol. 17 undefined-undefined
[24]  
Peltola Katriina(2017)Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial J. Clin. Oncol. 35 undefined-undefined
[25]  
Lee Jae Lyun(undefined)undefined undefined undefined undefined-undefined
[26]  
Heng Daniel Y C(undefined)undefined undefined undefined undefined-undefined
[27]  
Schmidinger Manuela(undefined)undefined undefined undefined undefined-undefined
[28]  
Agarwal Neeraj(undefined)undefined undefined undefined undefined-undefined
[29]  
Sternberg Cora N(undefined)undefined undefined undefined undefined-undefined
[30]  
McDermott David F(undefined)undefined undefined undefined undefined-undefined
123456789